Here, through a combination of in vitro and in vivo studies and the use of patient samples, we demonstrate that the histone acetyltransferase major histocompatibility complex (MHC) class II transactivator (CIITA), expressed in osteocytes, contributes to myeloma-induced bone lesions. The gene discussed is CIITA; the disease is plasma cell myeloma.